Eli Lilly and Co
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read MorePromise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read MoreStocks building the largest moves midday: United Airlines, Travelers, Abbott Laboratories and a lot more
Check out out the companies producing headlines in midday buying and selling. United Airways — Shares surged 14% right after the airline posted a narrower-than-expected reduction in the very first quarter. Quarterly profits arrived in at $12.54 billion, topping an LSEG estimate of $12.45 billion. Tourists Companies — The insurance policies stock fell 8% just […]
Read MoreMost doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according […]
Read MoreStocks producing the biggest premarket moves: Eli Lilly, Vacationers, United Airways, Alcoa and additional
Verify out the corporations producing the largest moves in premarket buying and selling: Eli Lilly , ResMed — Eli Lilly’s inventory moved 2% increased following the pharmaceutical giant’s announcement that its body weight loss drug Zepbound showed the probable to handle individuals with obstructive snooze apnea. Shares of ResMed, which makes devices to deal with […]
Read MoreEli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The […]
Read MoreEU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator […]
Read MoreDiabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor disability […]
Read MoreHealthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drugmakers spent big on advertisements for weight loss and diabetes treatments last year […]
Read MoreAltimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage trial, a finding that could set it apart in a potentially crowded market. Altimmune is one of several smaller biotech companies that are pushing to compete directly with Novo Nordisk and Eli Lilly […]
Read More